Allan Vaag
61 – 79 of 79
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- 3
- 4
- next »
- 2010
-
Mark
Impact of rs361072 in the Phosphoinositide 3-Kinase p110 beta Gene on Whole-Body Glucose Metabolism and Subunit Protein Expression in Skeletal Muscle
(
- Contribution to journal › Article
-
Mark
Insulin regimens in type 2 diabetes.
(
- Contribution to journal › Letter
-
Mark
Akt influences glycogen synthase in skeletal muscle through regulation of NH2-terminal phosphorylation
2010) 46th Annual Meeting of the European-Association-for-the- Study-of-Diabetes (EASD) In Diabetologia 53(Suppl. 1). p.696-696(
- Contribution to journal › Published meeting abstract
-
Mark
Differential aetiology and impact of phosphoinositide 3-kinase (PI3K) and Akt signalling in skeletal muscle on in vivo insulin action
(
- Contribution to journal › Article
-
Mark
Deoxyribonucleic Acid Methylation and Gene Expression of PPARGC1A in Human Muscle Is Influenced by High-Fat Overfeeding in a Birth-Weight-Dependent Manner.
(
- Contribution to journal › Article
- 2009
-
Mark
Retinol-Binding Protein 4 in Twins Regulatory Mechanisms and Impact of Circulating and Tissue Expression Levels on Insulin Secretion and Action
(
- Contribution to journal › Article
-
Mark
Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia
(
- Contribution to journal › Article
-
Mark
Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial
(
- Contribution to journal › Article
-
Mark
Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes
(
- Contribution to journal › Article
-
Mark
Skeletal muscle structural lipids improve during weight-maintenance after a very low calorie dietary intervention
(
- Contribution to journal › Article
-
Mark
Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
(
- Contribution to journal › Article
-
Mark
Functional Variant Disrupts Insulin Induction of USF1 Mechanism for USF1-Associated Dyslipidemias
(
- Contribution to journal › Article
- 2008
-
Mark
Sex and muscle structural lipids in obese subjects - an impact on insulin action?
(
- Contribution to journal › Article
-
Mark
Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes
(
- Contribution to journal › Article
-
Mark
Sustained postprandial decrease in plasma levels of LDL cholesterol in patients with type-2 diabetes mellitus
(
- Contribution to journal › Article
-
Mark
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes
(
- Contribution to journal › Article
- 2007
-
Mark
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial
(
- Contribution to journal › Article
-
Mark
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
(
- Contribution to journal › Article
-
Mark
Non-obese patients with type 2 diabetes and prediabetic subjects: distinct phenotypes requiring special diabetes treatment and (or) prevention?
(
- Contribution to journal › Article
- « previous
- 1
- 2
- 3
- 4
- next »